Clinical trial
A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® (Naftifine Hydrochloride) Gel 2% in Patients With Tinea Pedis.
NCT02335255 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® (Naftifine Hydrochloride) Gel 2% in Patients With Tinea Pedis.
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 27, 2014
- Completion date
- May 15, 2018
- Enrollment
- 1,519 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.